Anti Tümör Nekroz Faktör Alfa Tedavilere Dirençli veya Yan Etki Gelişen Romatoid Artrit Olgularında Rituksimabin Etkinlik ve Güvenilirliği

Cilt: 37 Sayı: 3 1 Eylül 2011
  • Ediz Dalkılıç
  • Nihan Alkış
  • Güven Özkaya
  • Mahmut Yavuz
  • Mustafa Güllülü
  • Kamil Dilek
  • Alpaslan Ersoy
  • Ayşe Nur Bayındır
  • Mustafa Yurtkuran
  • Ayşe Çefle
Uludağ Üniversitesi Tıp Fakültesi Dergisi Kapak
Uludağ Üniversitesi Tıp Fakültesi Dergisi
PDF İndir
EN TR

Rituximab Efficacy and Safety in Patients with Rheumatoid arthritis That are Refractory or Intolerable to Anti Tumor Necrosis Factor Alpha Agents

Öz

In this study, we evaluated the efficiency and safety of rituximab (RIT) treatment in patients with rheumatoid arthritis(RA) who were ina-dequate responders to anti tumor necrosis alpha (antiTNFα) agents or patients that can not tolerate antiTNFα agents because of adverse events. Twenty two patients with RA were enrolled to the study. Disease activity score(DAS 28) before and after (3. month) the RIT treat-ment, acute phase reactants, number of antiTNFα agents before RIT therapy and adverse events were analysed. Rheumatoid factor was positive in 18 of the 22 patients. Seventeen of the 22 patients were inadequate responders to antiTNFα agents, 2 patients developed malig-nancy and in 3 patients antiTNFα agents could not be used due to other adverse events. In cross sectional analysis of the 3. month, a signifi-cant decrease was seen in DAS28 from 5,9 to 4,8 (n=15, p

Anahtar Kelimeler

Ayrıntılar

Birincil Dil

İngilizce

Konular

-

Bölüm

-

Yazarlar

Ediz Dalkılıç Bu kişi benim

Nihan Alkış Bu kişi benim

Güven Özkaya Bu kişi benim

Mahmut Yavuz Bu kişi benim

Mustafa Güllülü Bu kişi benim

Kamil Dilek Bu kişi benim

Alpaslan Ersoy Bu kişi benim

Ayşe Nur Bayındır Bu kişi benim

Mustafa Yurtkuran Bu kişi benim

Ayşe Çefle Bu kişi benim

Yayımlanma Tarihi

1 Eylül 2011

Gönderilme Tarihi

1 Eylül 2011

Kabul Tarihi

-

Yayımlandığı Sayı

Yıl 2011 Cilt: 37 Sayı: 3

IZ

https://izlik.org/JA39CE68SE

Kaynak Göster

RIS / Bibtex
APA
Dalkılıç, E., Alkış, N., Özkaya, G., Yavuz, M., Güllülü, M., Dilek, K., Ersoy, A., Bayındır, A. N., Yurtkuran, M., & Çefle, A. (2011). Rituximab Efficacy and Safety in Patients with Rheumatoid arthritis That are Refractory or Intolerable to Anti Tumor Necrosis Factor Alpha Agents. Journal of Uludağ University Medical Faculty, 37(3), 127-130. https://izlik.org/JA39CE68SE
AMA
1.Dalkılıç E, Alkış N, Özkaya G, vd. Rituximab Efficacy and Safety in Patients with Rheumatoid arthritis That are Refractory or Intolerable to Anti Tumor Necrosis Factor Alpha Agents. Uludağ Tıp Derg. 2011;37(3):127-130. https://izlik.org/JA39CE68SE
Chicago
Dalkılıç, Ediz, Nihan Alkış, Güven Özkaya, vd. 2011. “Rituximab Efficacy and Safety in Patients with Rheumatoid arthritis That are Refractory or Intolerable to Anti Tumor Necrosis Factor Alpha Agents”. Journal of Uludağ University Medical Faculty 37 (3): 127-30. https://izlik.org/JA39CE68SE.
EndNote
Dalkılıç E, Alkış N, Özkaya G, Yavuz M, Güllülü M, Dilek K, Ersoy A, Bayındır AN, Yurtkuran M, Çefle A (01 Eylül 2011) Rituximab Efficacy and Safety in Patients with Rheumatoid arthritis That are Refractory or Intolerable to Anti Tumor Necrosis Factor Alpha Agents. Journal of Uludağ University Medical Faculty 37 3 127–130.
IEEE
[1]E. Dalkılıç vd., “Rituximab Efficacy and Safety in Patients with Rheumatoid arthritis That are Refractory or Intolerable to Anti Tumor Necrosis Factor Alpha Agents”, Uludağ Tıp Derg, c. 37, sy 3, ss. 127–130, Eyl. 2011, [çevrimiçi]. Erişim adresi: https://izlik.org/JA39CE68SE
ISNAD
Dalkılıç, Ediz - Alkış, Nihan - Özkaya, Güven - Yavuz, Mahmut - Güllülü, Mustafa - Dilek, Kamil - Ersoy, Alpaslan - Bayındır, Ayşe Nur - Yurtkuran, Mustafa - Çefle, Ayşe. “Rituximab Efficacy and Safety in Patients with Rheumatoid arthritis That are Refractory or Intolerable to Anti Tumor Necrosis Factor Alpha Agents”. Journal of Uludağ University Medical Faculty 37/3 (01 Eylül 2011): 127-130. https://izlik.org/JA39CE68SE.
JAMA
1.Dalkılıç E, Alkış N, Özkaya G, Yavuz M, Güllülü M, Dilek K, Ersoy A, Bayındır AN, Yurtkuran M, Çefle A. Rituximab Efficacy and Safety in Patients with Rheumatoid arthritis That are Refractory or Intolerable to Anti Tumor Necrosis Factor Alpha Agents. Uludağ Tıp Derg. 2011;37:127–130.
MLA
Dalkılıç, Ediz, vd. “Rituximab Efficacy and Safety in Patients with Rheumatoid arthritis That are Refractory or Intolerable to Anti Tumor Necrosis Factor Alpha Agents”. Journal of Uludağ University Medical Faculty, c. 37, sy 3, Eylül 2011, ss. 127-30, https://izlik.org/JA39CE68SE.
Vancouver
1.Ediz Dalkılıç, Nihan Alkış, Güven Özkaya, Mahmut Yavuz, Mustafa Güllülü, Kamil Dilek, Alpaslan Ersoy, Ayşe Nur Bayındır, Mustafa Yurtkuran, Ayşe Çefle. Rituximab Efficacy and Safety in Patients with Rheumatoid arthritis That are Refractory or Intolerable to Anti Tumor Necrosis Factor Alpha Agents. Uludağ Tıp Derg [Internet]. 01 Eylül 2011;37(3):127-30. Erişim adresi: https://izlik.org/JA39CE68SE

ISSN: 1300-414X, e-ISSN: 2645-9027

Uludağ Üniversitesi Tıp Fakültesi Dergisi "Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License" ile lisanslanmaktadır.


Creative Commons License
Journal of Uludag University Medical Faculty is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

2023